CIDRAP newsletters options
Two doses were 92% effective in preventing infection, but 1 dose was 74% effective against COVID-related hospitalization and 72% effective at preventing death.
Americans with COVID-19 antibodies displayed 10-fold increased protection against infection 90 days after testing compared with those who had no antibodies, according to a study published today in JAMA Internal Medicine.
The European Centre for Disease Prevention and Control (ECDC) today issued a risk assessment regarding human H5N8 avian flu cases reported recently in Russia, with the caveat that it was basing its report on very limited data.
Russia recently reported seven infections in people who worked at poultry facilities in the south. They reportedly had asymptomatic infections, and no human-to-human transmission was noted.
Elsewhere, the UK says new cases involving SARS-CoV-2 variants are dropping sharply.
The authors say the data support the CDC's prioritization of this group for vaccination.
Pending FDA approval, Johnson & Johnson is prepared to deliver 100 million doses by mid-summer.
Data indicate amoxicillin-clavulanate is safe and effective and may cut the risk of fluoroquinolone-related harms.
Patients critically ill with COVID-19 infections had significantly lower levels of antibodies against seasonal human coronaviruses (HCoVs) OV43 and HKU1 than those with mild to severe infections, according to a German study published yesterday in the International Journal of Infectious Diseases.
CARB-X announced today that it is awarding up to $2.2 million to the University of Queensland's Institute for Molecular Bioscience (IMB) to continue developing new compounds designed to boost antibiotics that have become ineffective against drug-resistant bacterial infections.
Tedros urges vaccine companies to prioritize COVAX contracts and for high-income countries to avoid signing new contracts that deplete the global supply.
Seven poultry workers at a plant in southern Russia are infected; the nation first reported the strain in poultry last year.
It took only 1 month for the nation's death tally to grow from 400,000 to 500,000.
Experts in health-system pharmacy say the potential for major disruptions will increase.
Giving the second dose at 3 months resulted in up to 47% greater protection than giving it at 6 weeks.
The Australian government late last week released a One Health Master Action Plan (OHMAP) to support the country's 2o20 antimicrobial resistance (AMR) strategy.
People who received their flu vaccine were less likely to test positive for COVID-19, and if they were infected with the virus, they were less likely to need hospitalization, mechanical ventilation, or a longer hospital stay, according to a study published today in the American Journal of Infection Control.
G7 leaders pledge more than $4 billion more to COVAX; deliveries to lower-resource nations begin soon.
New studies and regulatory requests from Pfizer could pave the way for more pregnant women to be vaccinated and more developing nations to receive vaccine.
One of the studies is based on psychiatric assessment after COVID-19 emergency care, and the other is based on a US web survey of adults.
Provincial health officials in the Democratic Republic of the Congo's (DRC's) North Kivu province yesterday reported two more Ebola cases, one of them more than 90 miles from Butembo, the main epicenter, according to Reuters.
The new cases raise the outbreak total to six, with the number of deaths remaining at two. One of the new patients is from Katwa, about 6 miles from Butembo. The other is from Manguredjipa, about 93 miles away.
